What is Novavax's software and technology licenses, net?

Novavax (NVAX) reported software and technology licenses, net of $15.95M in Q1 2026.

How has Novavax's software and technology licenses, net changed year-over-year?

Novavax's software and technology licenses, net decreased by 27.2% year-over-year, from $21.9M to $15.95M.

What is the long-term trend for Novavax's software and technology licenses, net?

Over 5 years (2020 to 2025), Novavax's software and technology licenses, net has grown at a 5.3% compound annual growth rate (CAGR), from $13.22M to $17.08M.

Novavax NVAX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

ModernaMRNA

——

Roivant SciencesROIV

——

Merck & Co.MRK

——

Vaxcyte, Inc.PCVX

——

Viridian Therapeutics, Inc.VRDN

——

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Cash & equivalents$228.4M-13.3%

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+41.0%

Enterprise value$1.53B+83.6%

P/S2.5×+1.6×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's software and technology licenses, net?: Novavax (NVAX) reported software and technology licenses, net of $15.95M in Q1 2026.
How has Novavax's software and technology licenses, net changed year-over-year?: Novavax's software and technology licenses, net decreased by 27.2% year-over-year, from $21.9M to $15.95M.
What is the long-term trend for Novavax's software and technology licenses, net?: Over 5 years (2020 to 2025), Novavax's software and technology licenses, net has grown at a 5.3% compound annual growth rate (CAGR), from $13.22M to $17.08M.